DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

* Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study * Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluated * Findings support Lexaria's expanding strategic partnering outreach activities by evidencing DehydraTECH benefits for oral delivery of next generation GLP-1 drugs

KELOWNA, BC / ACCESS Newswire / August 24, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that blood plasma pharmacokinetic ("PK") bioanalysis testing has been completed in its 2026 Animal Study #2 (GLP-1-A26-2, the "Study"). The Study examined oral delivery of 2 next-generation glucagon-like peptide-1 ("GLP-1") drugs, amycretin and retatrutide, in a total of 18 different study arms in dogs following formulation and processing using Lexaria's patented DehydraTECH(TM) ("DHT") drug delivery enabling platform technology formulated in oral tablet and capsule formats.